(Q37106742)

18 August 2017

1 reference

title

Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps (English)

1 reference

18 August 2017

1 reference

5

1 reference

18 August 2017

Harrie Buist

7

0 references

Jos Bessems

object named as

Jos Bessems

4

0 references

Walter Schmitt

object named as

Walter Schmitt

12

0 references

Ursula Gundert-Remy

10

object named as

Ursula Gundert-Remy

1 reference

18 August 2017

George Loizou

1

1 reference

18 August 2017

Martin Spendiff

2

1 reference

18 August 2017

Hugh A Barton

3

1 reference

18 August 2017

Michel Bouvier d'Yvoire

6

1 reference

18 August 2017

Harvey J Clewell

8

1 reference

18 August 2017

Bette Meek

9

1 reference

18 August 2017

Gerhard Goerlitz

11

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Regulatory Toxicology and Pharmacology

18 August 2017

1 reference

18 August 2017

50

1 reference

18 August 2017

3

1 reference

18 August 2017

400-411

1 reference

Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform

18 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Applying simulation modeling to problems in toxicology and risk assessment--a short perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

The Integrated Use of Alternative Methods in Toxicological Risk Evaluation - ECVAM Integrated Testing Strategies Task Force Report 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

IPCS framework for analyzing the relevance of a cancer mode of action for humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

IPCS framework for analyzing the relevance of a noncancer mode of action for humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Evaluation of physiologically based pharmacokinetic models for use in risk assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

A physiologically based pharmacokinetic model for retinoic acid and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

A physiological toxicokinetic model for inhaled propylene oxide in rat and human with special emphasis on the nose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

An Integrated Approach to the Prediction of Systemic Toxicity using Computer-based Biokinetic Models and Biological In vitro Test Methods: Overview of a Prevalidation Study Based on the ECITTS Project.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

PBPK models in risk assessment--A focus on chloroprene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Kinetics of propylene oxide metabolism in microsomes and cytosol of different organs from mouse, rat, and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

A mathematical model for the absorption and metabolism of formaldehyde vapour by humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Physiologically based pharmacokinetic modelling of human exposure to 2-butoxyethanol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Optimal design for multivariate response pharmacokinetic models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Biomonitoring equivalents: a screening approach for interpreting biomonitoring results from a public health risk perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Extrapolation of in vitro enzyme induction data to humans in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Propylene oxide in blood and soluble nonprotein thiols in nasal mucosa and other tissues of male Fischer 344/N rats exposed to propylene oxide vapors--relevance of glutathione depletion for propylene oxide-induced rat nasal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

In vitro to in vivo extrapolation for trichloroethylene metabolism in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Practical application of kinetic data in risk assessment--an IPCS initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

A framework for human relevance analysis of information on carcinogenic modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Lumping of whole-body physiologically based pharmacokinetic models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Evaluation (not validation) of quantitative models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Dosimetry by means of DNA and hemoglobin adducts in propylene oxide-exposed rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Practicing safe modeling: GLP for biologically based mechanistic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

The use and abuse of models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2008.01.011

10.1016/J.YRTPH.2008.01.011

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference